Catalyst Wire Dossier Catalyst Wire Dossier

GSK3542503 hydrochlorothiazide + amiloride hydrochloride 50 mg: 5 mg tablets

hydrochlorothiazide + amiloride hydrochloride · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GSK3542503 hydrochlorothiazide + amiloride hydrochloride 50 mg: 5 mg tablets, covering 2018-08-31 to 2018-08-31. Get the full timeline:

Most recent: Clinical Trial Update: Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions [Phase 1]

See pricing